Home » Posts tagged with » ExeGi Pharma
ExeGi Pharma gets FDA orphan drug status for EXE-346 in pouchitis
ExeGi Pharma said that EXE-346 has been granted an orphan drug designation from the US Food and Drug Administration (FDA) for the prevention of disease relapse in pouchitis. EXE-346 is a live biotherapeutic (LBP) that contains a fixed-proportion of eight strains of live probiotic bacteria which are intended to be administered orally. Pouchitis is a […]
ExeGi Pharma announces probiotic Visbiome clinical trial in MS patients
September 10, 2019 No Comment
Visbiome clinical trial : ExeGi Pharma said that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be studying the company’s probiotic product Visbiome in multiple sclerosis (MS) patients in a new clinical trial. The clinical trial will look into the effects of probiotics on the gut microbiota and immune systems […]
Continue reading …
Business News Today
- PostBank Uganda launches new debit card – UnionPay PostCard
- Lightnet Group strikes partnership with Thailand’s Siam Commercial Bank
- JinkoSolar to divest stake in 1.2GW Sweihan Power Station in Abu Dhabi
- CBAK Energy to supply battery packs to EV manufacturer Kandi Vehicles
- Flanagan Associates acquired by World Insurance Associates
- Chinese lifestyle product retailer MINISO opens new store in Madrid
- Unilever to acquire Los Angeles-based SmartyPants Vitamins
- Bega Cheese to acquire Lion Dairy & Drinks for $412m
- Nestlé to sell Yinlu peanut milk and canned rice porridge businesses in China
- TEXRail extension project : Trinity Metro selects AECOM as project consultant
